Want to learn about the latest advances in obesity management? In this exclusive dialogue, two renowned experts: Prof. David E. Cummings, Endocrinologist and Professor of Medicine at the
University of Washington, internationally recognised for his pioneering research on the hormonal and metabolic mechanisms regulating appetite, body weight and glucose homeostasis and Dr.
Tham Kwang Wei, Senior Consultant Endocrinologist and Chairperson of the Singapore Association for the Study of Obesity (SASO), address current unmet needs in obesity
management. Bridging the gap between medical and surgical approaches, they explored how the Dual Incretin Receptor Agonist – Tirzepatide, is redefining patient care and transforming
obesity treatment management landscape.
University of Washington, internationally recognised for his pioneering research on the hormonal and metabolic mechanisms regulating appetite, body weight and glucose homeostasis and Dr.
Tham Kwang Wei, Senior Consultant Endocrinologist and Chairperson of the Singapore Association for the Study of Obesity (SASO), address current unmet needs in obesity
management. Bridging the gap between medical and surgical approaches, they explored how the Dual Incretin Receptor Agonist – Tirzepatide, is redefining patient care and transforming
obesity treatment management landscape.
Log In or Register as a healthcare professional to read the full article.
